Glucosylceramidase (Acid beta-glucosidase) (GBA1)

Glucosylceramidase (also known as acid beta-glucosidase or beta-glucocerebrosidase) is a critical lysosomal enzyme responsible for the hydrolysis of glucosylceramide into glucose and ceramide [1, 4]. It plays a central role in sphingolipid metabolism and maintaining cellular lipid homeostasis within the lysosome [1]. Mutations in the GBA1 gene lead to a deficiency in enzyme activity, causing the lysosomal storage disorder known as Gaucher disease, which is characterized by the accumulation of glucosylceramide in macrophages, often referred to as Gaucher cells [2]. Furthermore, GBA1 mutations are recognized as the most significant genetic risk factor for Parkinson's disease and Lewy body dementia, where reduced enzyme activity is thought to promote the aggregation of alpha-synuclein [3]. Current therapeutic interventions primarily involve enzyme replacement therapy (ERT) using recombinant forms of the enzyme to restore metabolic function in Gaucher disease patients [2, 4]. Emerging research also focuses on pharmacological chaperones, such as ambroxol, designed to stabilize and enhance the activity of endogenous mutant GBA1 in both lysosomal and neurodegenerative contexts [3, 5]. Sources: [1] UniProt (P04062) [2] NIH Genetic and Rare Diseases Information Center (GARD) - Gaucher Disease [3] Parkinson's Foundation - GBA1 and Parkinson's [4] PubChem Compound Summary - Glucosylceramidase [5] PubMed - Pharmacological Chaperones for GBA1

Other names

Acid beta-glucosidaseBeta-glucocerebrosidaseGlucocerebrosidaseGBAGCBGlucosylceramide beta-glucosidaseD-glucosyl-N-acylsphingosine glucohydrolase

Enzyme replacement therapy (ERT) and pharmacological chaperone therapy (PCT)